BOSTON, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Galecto, Inc. (GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced positive ...

BOSTON, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced positive ...

Pelabresib plus Jakafi showed superior spleen volume reduction and symptom improvement compared to Jakafi alone in myelofibrosis patients. The combination therapy resulted in fewer red blood cell ...

Chimeric antigen receptor-T cell (CAR-T cell) therapies have been a significant advance in the field of cancer immunotherapeutics in recent years, particularly for B-cell malignancies. Yet, this ...

CK0804, a novel Treg therapy, gains FDA orphan drug status for myelofibrosis, promising new hope for patients with limited treatment options. CK0804, an investigational allogeneic regulatory T cell ...

Medically reviewed by Doru Paul, MD Key Takeaways Myelosuppression is when bone marrow can't make enough blood cells.

"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...

Six of ten evaluable myelofibrosis patients who received GB2064 monotherapy for at least six months experienced a ≥ 1-grade reduction in collagen fibrosis of the bone marrow, validating LOXL2 as a ...